AI Terminal
Evonik Industries AG
Earnings Release • May 4, 2016
150_rns_2016-05-04_1e9500f1-fbd5-499a-bb47-d84384d013cc.html
Earnings Release
Open in ViewerOpens in native device viewer
News Details
Corporate | 4 May 2016 07:00
Evonik Industries AG: A solid first quarter – Outlook for 2016 confirmed
DGAP-News: Evonik Industries AG / Key word(s): Quarter Results
2016-05-04 / 07:00
The issuer is solely responsible for the content of this announcement.
Embargoed until: May 4, 2016, 7 a.m.
May 4, 2016
Key Financial Data:
January 1 to March 31, 2016 / Q1 2016
A solid first quarter-Outlook for 2016 confirmed
– Adjusted net income EUR254 million
– Adjusted EBITDA EUR565 million
– Adjusted EBITDA margin at a very good level of 18.2 percent
– Sales EUR3.1 billion
Essen . Evonik did well in the first quarter in challenging business conditions. “Following an exceptionally strong performance in 2015, our earnings are now back in line with the good level of the preceding years. Our business is still doing well and our products are in demand in the market,” said Klaus Engel, Chairman of the Executive Board of Evonik Industries.
The Resource Efficiency segment posted a pleasing development: While sales were steady it was able to raise earnings. In the Nutrition & Care segment, lower volumes and declining world market prices resulted in a drop in both sales and earnings. Lower selling prices, mainly as a result of a reduction in raw material costs, also held back the development of the Performance Materials segment.
Overall, the Evonik Group’s sales contracted by 9 percent to EUR3,106 million (Q1 2015: EUR3,425 million). While demand for Evonik products was stable overall, selling prices declined by 7 percentage points.
Adjusted EBITDA was EUR565 million, 13 percent lower than in the exceptionally strong prior-year period (Q1 2015: EUR650 million). The adjusted EBITDA margin remained very good at 18.2 percent, compared with 19.0 percent in the prior-year period. Adjusted EBIT fell 20 percent to EUR389 million. Adjusted net income was EUR254 million in the first quarter, down 21 percent from EUR320 million in the first quarter of 2015. Net income declined 6 percent to EUR240 million (Q1 2015: EUR256 million).
Capital expenditures for property, plant and equipment were EUR160 million in the first quarter of 2016, 15 percent below the prior-year level of EUR189 million. In the first quarter of 2016, the free cash flow was EUR161 million, compared with EUR179 million in the prior-year period.
Outlook confirmed
Evonik’s expectations for global economic conditions are unchanged: Overall the company anticipates slightly lower momentum in the global economy, with a year-on-year growth rate of 2.5 percent in 2016.
In these conditions, Evonik is confirming its outlook for the full year: Following a very successful year in 2015, the company expects to report slightly lower sales in 2016 and adjusted EBITDA of between EUR2.0 billion and EUR2.2 billion.
Segment performance
In the first quarter of 2016, the Nutrition & Care segment’s sales fell 15 percent to EUR1,047 million. Alongside lower volumes, the main reason for this was the decline in world market prices. Adjusted EBITDA was EUR293 million, which was below the very high prior-year level of EUR353 million. The adjusted EBITDA margin remains at an excellent level of 28.0 percent.
Driven by good global demand, the Resource Efficiency segment registered pleasing volume growth, but selling prices declined slightly overall. Sales were virtually unchanged year-on-year at EUR1,120 million. Adjusted EBITDA improved 5 percent to EUR256 million. The adjusted EBITDA margin increased from 21.7 percent to a very good level of 22.9 percent.
Sales declined 9 percent to EUR772 million in the Performance Materials segment. This was due to the continued decline in raw material prices, which led to a further reduction in selling prices. By contrast, volumes increased substantially. Adjusted EBITDA was 11 percent lower at EUR64 million. The adjusted EBITDA margin was 8.3 percent, down slightly from 8.5 percent in the first quarter of 2015.
Evonik Group: Excerpt from the income statement
| (in EUR million) | Q1 2016 | Q1 2015 | Change in % |
| Sales | 3,106 | 3,425 | -9 |
| Adjusted EBITDA | 565 | 650 | -13 |
| Adjusted EBIT | 389 | 485 | -20 |
| Adjustments | -13 | -37 | |
| Financial result | -34 | -63 | |
| Income before income taxes, continuing operations | 342 | 385 | -11 |
| Income taxes | -98 | -115 | |
| Income after taxes, continuing operations | 244 | 270 | -10 |
| Income after taxes, discontinued operations | – | -11 | |
| Income after taxes | 244 | 259 | -6 |
| thereof attributable to non-controlling interests | 4 | 3 | |
| Net income | 240 | 256 | -6 |
| Adjusted net income | 254 | 320 | -21 |
Prior-year figures restated
Segment performance
| Sales | Adj. EBITDA | |||||
| Q1 2016 in EUR million |
Q1 2015 in EUR million |
Change in % |
Q1 2016 in EUR million |
Q1 2015 in EUR million |
Change in % | |
| Nutrition & Care | 1,047 | 1,229 | -15 | 293 | 353 | -17 |
| Resource Efficiency | 1,120 | 1,124 | – | 256 | 244 | 5 |
| Performance Materials | 772 | 851 | -9 | 64 | 72 | -11 |
| Services | 166 | 207 | -20 | 35 | 46 | -24 |
| Other operations | 1 | 14 | -83 | -65 | ||
| Group | 3,106 | 3,425 | -9 | 565 | 650 | -13 |
Prior-year figures restated
Employees by segment
| March 31, 2016 | Dec. 31, 2015 | |
| Nutrition & Care | 7,347 | 7,165 |
| Resource Efficiency | 8,652 | 8,662 |
| Performance Materials | 4,384 | 4,380 |
| Services | 12,710 | 12,668 |
| Other operations | 507 | 701 |
| Group | 33,600 | 33,576 |
Company information
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around EUR13.5 billion and an operating profit (adjusted EBITDA) of about EUR2.47 billion.
Disclaimer
In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
Contact:
| Tim Lange Head of Investor Relations Phone +49 201 177-3150 [email protected] |
| Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone +49 201 177-01 Telefax +49 201 177-3475 www.evonik.com Supervisory Board Dr. Werner Müller, Chairman Executive Board Dr. Klaus Engel, Chairman Dr. Ralph Sven Kaufmann Christian Kullmann Thomas Wessel Ute Wolf Registered office Essen Registered court Essen local court Commercial registry B 19474 VAT ID no. DE 811160003 |
2016-05-04 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | Evonik Industries AG |
| Rellinghauser Straße 1-11 | |
| 45128 Essen | |
| Germany | |
| Phone: | +49 (0) 201 177-01 |
| Fax: | +49 (0) 201 177-3475 |
| E-mail: | [email protected] |
| Internet: | www.evonik.com |
| ISIN: | DE000EVNK013, XS0911405784 |
| WKN: | EVNK01, A1TM7T |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart; Terminbörse EUREX; Luxemburg |
| End of News | DGAP News Service |